Hospira Rebounding as Remediation Wraps Up

Drug GMP Report
A A
More than three years after Hospira’s Rocky Mount, N.C., plant was warned for lax quality control, prompting a painful manufacturing slowdown and a costly remediation, the drugmaker expects to near the “top end” of production capability in 2014, Hospira’s chief said last month.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00